Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare

Cellecta  

Charles River Discovery

Elsevier 

 NanoString     

 SeraCare 

Silicon Biosystems   

 Streck 

 TriMetis


XIFIN

  View All Sponsors 


Cambridge Healthtech Institute’s Fifth Annual 

Translational Models in Oncology and Immuno-Oncology 

Tumor Models and Strategies to Inform Clinical Development

February 20-22, 2017 | Moscone North Convention Center | San Francisco, CA
Part of the 24th International Molecular Medicine Tri-Conference

 

Despite tremendous progress in our understanding of cancer biology, the majority of novel anticancer therapies fail in clinical trials, which indicates deficiencies in conventional translational approaches. In most cases, preclinical data have overpredicted clinical efficacy in oncology. With the rise of immuno-oncology, the challenge of in vivo pharmacology was enhanced by the differences in mouse and human immune systems that further damage the predictiveness of preclinical data. The phenomenon of cancer heterogeneity and subsequent drug resistance adds another dimension to the preclinical cancer research warranting active work on combination cancer regimens. Better models and approaches are clearly in high and urgent demand and have been worked on by industry and academia scientists. Cambridge Healthtech Institute’s Fifth Annual Translational Models in Oncology and Immuno-Oncology conference is designed to highlight cutting edge advances in in vivo, in vitro and in silico modeling and to facilitate a discussion about effective translational approaches in cancer research.

Who should attend: Cancer researchers working in the areas of discovery, in vivo pharmacology, cell pharmacology, preclinical studies, translational oncology and early clinical development.

Topics will include, but are not limited to:

  • Immunocompetent mouse models
  • PDX models and their applications
  • Humanized mouse models
  • Large scale in vivo screens
  • Next generation cell lines and 3-D models of cancer
  • Gene editing and genetic screens in in vivo and in vitro models
  • Strategies to increase translatability of preclinical results
  • Analyzing negative results, profiling failures, etc.
  • Bidirectional preclinical ↔ clinical info exchange

  • Optimizing clinical trial design by PDX integration
  • Response criteria for cancer immunotherapy
  • Changing IND requirements for cancer immunotherapy assessment 
  • Rational preclinical design of combination therapies
  • Modeling for combination therapy assessment
  • Biomarker-based selection in preclinical and clinical trials
  • Epigenetic priming for immunotherapy
  • Modeling for combination therapy assessment
  • Predicting toxicity of immunotherapies

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is July 15, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
T: (+1) 781-972-5496
E: mfilshtinsky@healthtech.com

Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z) 
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com